Syndax Pharmaceuticals, Inc.
SNDX
$18.79
-$0.33-1.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 102.19M | 68.82M | 43.72M | 23.68M | 16.00M |
| Total Other Revenue | 9.36M | 9.36M | -- | -- | -- |
| Total Revenue | 111.55M | 78.18M | 43.72M | 23.68M | 16.00M |
| Cost of Revenue | 137.12M | 136.63M | 121.78M | 120.90M | 109.67M |
| Gross Profit | -25.57M | -58.45M | -78.06M | -97.22M | -93.67M |
| SG&A Expenses | 167.44M | 153.63M | 138.89M | 120.88M | 105.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 418.21M | 416.99M | 387.39M | 363.35M | 337.21M |
| Operating Income | -306.65M | -338.81M | -343.67M | -339.67M | -321.21M |
| Income Before Tax | -311.58M | -334.99M | -331.20M | -318.76M | -297.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -311.58 | -334.99 | -331.20 | -318.76 | -297.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -311.58M | -334.99M | -331.20M | -318.76M | -297.06M |
| EBIT | -306.65M | -338.81M | -343.67M | -339.67M | -321.21M |
| EBITDA | -306.65M | -338.80M | -343.66M | -339.66M | -321.20M |
| EPS Basic | -3.62 | -3.90 | -3.87 | -3.73 | -3.63 |
| Normalized Basic EPS | -2.26 | -2.44 | -2.42 | -2.33 | -2.27 |
| EPS Diluted | -3.62 | -3.90 | -3.87 | -3.73 | -3.64 |
| Normalized Diluted EPS | -2.26 | -2.44 | -2.42 | -2.33 | -2.27 |
| Average Basic Shares Outstanding | 344.92M | 343.73M | 342.67M | 341.71M | 328.44M |
| Average Diluted Shares Outstanding | 344.92M | 343.73M | 342.67M | 341.71M | 328.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |